Valuation: Intra-Cellular Therapies, Inc.

Market Cap 14.02B 12.45B 11.65B 10.56B 19.94B 1,352B 20.08B 140B 54.41B 690B 52.63B 51.5B 2,217B P/E 2023
-49.2x
P/E 2024 -115x
Enterprise Value 13.04B 11.57B 10.83B 9.82B 18.54B 1,257B 18.67B 130B 50.59B 641B 48.94B 47.89B 2,061B EV / Sales 2023
13.8x
EV / Sales 2024 11.6x
Free-Float
95.68%
Yield 2023 *
-
Yield 2024 -
3 years 45.5
Extreme 45.5
131.98
5 years 34.43
Extreme 34.43
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2022-03-31
Compliance Officer 64 2019-07-01
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap. Importance
4/2/25 Issuer saleCompany 10,000 0.0094%
4/2/25 Issuer sale

Director

55,511 0.0522%
4/2/25 Issuer sale

Chief Technology Officer

265,944 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--%-.--%+156.91% 14.02B
+1.26%-2.30%+37.82%+113.76% 1,019B
+0.73%-6.31%+35.06%+62.14% 610B
+0.35%+0.15%+14.01%+80.87% 470B
+1.72%-4.54%+59.14%+37.01% 344B
+0.26%-1.58%+21.97%+41.79% 336B
+0.60%-3.48%+11.37%+34.33% 266B
+1.65%-4.27%-5.47%+9.69% 241B
-0.09%-3.71%+35.15%+51.88% 218B
-0.28%-5.24%+27.99%+93.08% 179B
Average +0.33%-3.26%+23.70%+68.15% 369.69B
Weighted average by Cap. +0.05%-3.49%+29.38%+70.39%

Financials

2023 2024
Net sales 464M 412M 386M 350M 660M 44.76B 665M 4.63B 1.8B 22.84B 1.74B 1.71B 73.41B 681M 604M 566M 513M 968M 65.63B 975M 6.79B 2.64B 33.48B 2.56B 2.5B 108B
Net income -140M -124M -116M -105M -199M -13.46B -200M -1.39B -542M -6.87B -524M -513M -22.08B -74.68M -66.29M -62.03M -56.23M -106M -7.2B -107M -745M -290M -3.67B -280M -274M -11.81B
Net Debt -481M -427M -400M -362M -684M -46.37B -689M -4.8B -1.87B -23.65B -1.81B -1.77B -76.04B -984M -874M -817M -741M -1.4B -94.86B -1.41B -9.82B -3.82B -48.39B -3.69B -3.61B -156B
Projected Income Statement - Annual - Intra-Cellular Therapies, Inc.
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Intra-Cellular Therapies, Inc.
  1. Stock Market
  2. Stocks
  3. ITCI Stock